Hopes that angiogenesis inhibition could improve outcomes when used adjuvantly in colorectal cancer received a setback at the end of April, with the announcement that the NSABP C-08 trial had failed to meet its primary endpoint. Recent research into how tumours respond to these drugs may help explain the disappointing results.
Leave a Reply